ArticleCase reports in pathology2026
Pulmonary Adenoleiomyomatous Hamartoma: Case Report of a Rare Entity With Comprehensive Literature Review.
Article in Case reports in pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pulmonary Adenoleiomyomatous Hamartoma: Case Report of a Rare Entity With Comprehensive Literature Review.Case reports in pathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary adenoleiomyomatous hamartomas represent a rare and intriguing entity in pulmonary pathology. This study presents a unique case of adenoleiomyomatous hamartoma along with a comprehensive analysis of 14 cases identified through a systematic review of the literature. A 69-year-old Caucasian female presented for evaluation of an incidentally discovered, PET nonavid and slow-growing pleural-based nodule in the medial aspect of the lower lobe of her right lung. The biopsy showed pulmonary parenchyma with chronic inflammation, fibrosis, and smooth muscle hyperplasia. Subsequently, a diagnosis of pulmonary adenoleiomyomatous hamartoma was made on wedge resection after the exclusion of differential diagnoses. The literature review suggests a mean age of 54.5 ± 3.5 years at diagnosis and male predominance with a male-to-female ratio of 6:1. Follow-up data on our patient and literature suggest a uniformly benign course. The key takeaways include the indolent radiologic growth pattern. From a pathologic standpoint, excluding mimics such as solitary fibrous tumor, inflammatory myofibroblastic tumor, PEComa, Langerhans cell histiocytosis, mesothelial proliferations, and IgG4-related diseases is crucial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.